Zielgerichtete Therapie bei BRAF-mutiertem metastasierten papillären Schilddrüsenkarzinom und malignen Melanom
Bender-Säbelkampf S, Tüting T, Alter M, Horbrügger M (2019)
Publication Type: Conference contribution, Abstract of a poster
Publication year: 2019
Journal
Book Volume: 17
Pages Range: 25-91
Conference Proceedings Title: Abstractband anlässlich des 29. Deutschen Hautkrebskongresses (ADO–Jahrestagung)
Event location: Ludwigshafen
Issue: S5
DOI: 10.1111/ddg.13905
Abstract
We like to present a case study of an 80-year old male with a metastatic papillary thyroid cancer and malignant melanoma.
A left hemithyroidectomy was performed in 2017. Due to a former existing single-sided recurrent laryngeal nerve palsy a R0-resection could not been carried through. The subsequent therapy consisted of thyroid hormone substitution and radio iodine therapy. Up until now the thyroid cancer cells don’t show an uptake anymore, further radio iodine therapy is therefor contraindicated. Further PET-CTs and ultrasounds showed an increase in size with a subtotal stenosis of the oesophagus and severe dysphagia.
In January 2019 we excised a nodular melanoma occipital right. The subsequent staging showed progressive cervical lymph node metastasis and pulmonary lesions. We assign the infiltration of oesophagus and neck as metastasis of the thyroid cancer whereas the pulmonal lesions we see as metastatic stage IV melanoma. Via genomic sequencing there was a BRAF-V600-E mutation found in both melanoma and the papillary thyroid cancer.
A prevalence of BRAF-mutations in thyroid cancer are found in 20–50 % and for malignant melanoma in 40–60 % (1). As there is currently no officially approved targeted therapy for BRAF mutant thyroid cancer in Europe, a few clinical studies (2) using targeted therapy however showed a therapy response rate of 70 %. As this therapy is also already indicated for mutation positive metastatic malignant melanoma and non-small cell lung cancer, the FDA recently approved Dabrafenib and Trametinib as targeted therapy in BRAF-positive anaplastic thyroid cancer. Due to the BRAF-positive malignant melanoma in our case, we could initiate a targeted therapy immediately. Recent studies showed a higher standardised uptake value and FDG PET acitivity in BRAF-positive thyroid cancer cells which leads to the hope that through a targeted therapy the once iodine-resistant thyroid cells of our patient could possibly regulate their uptake level for radio iodine therapy to be successful once again.
Authors with CRIS profile
Involved external institutions
How to cite
APA:
Bender-Säbelkampf, S., Tüting, T., Alter, M., & Horbrügger, M. (2019, August). Zielgerichtete Therapie bei BRAF-mutiertem metastasierten papillären Schilddrüsenkarzinom und malignen Melanom. Poster presentation at 29. Deutscher Hautkrebskongress, Ludwigshafen, DE.
MLA:
Bender-Säbelkampf, Sophia, et al. "Zielgerichtete Therapie bei BRAF-mutiertem metastasierten papillären Schilddrüsenkarzinom und malignen Melanom." Presented at 29. Deutscher Hautkrebskongress, Ludwigshafen 2019.
BibTeX: Download